Interplay between statins and PPARs in improving cardiovascular outcomes: A double-edged sword?

British Journal of Pharmacology

Volumn 165, Issue 2, 2012, Pages 373-379

  Balakumar, Pitchai ^a   Mahadevan, Nanjaian ^b  

^a Rajendra Institute of Technology and Sciences   (India)

^b RITS   (India)

Author keywords

cardiovascular complications; PPARs; statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FENOFIBRATE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TESAGLITAZAR;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; CARDIOVASCULAR EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DYSLIPIDEMIA; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIPID METABOLISM; MOLECULAR MECHANICS; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; RHABDOMYOLYSIS; TREATMENT OUTCOME;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 83755220049     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01597.x     Document Type: Review

References (56)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164: S1-S324.
2. Ali FY, Armstrong PC, Dhanji AR, Tucker AT, Paul-Clark MJ, Mitchell JA, et al,. (2009). Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol 29: 706-711.
3. Antons KA, Williams CD, Baker SK, Phillips PS, (2006). Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 119: 400-409. (Pubitemid 44294467)
4. Arora MK, Reddy K, Balakumar P, (2010). The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. Eur J Pharmacol 636: 137-144.
5. Balakumar P, Jagadeesh G, (2010). Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared? Pharmacol Res 62: 365-383.
6. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M, (2007a). PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res 56: 91-98. (Pubitemid 47304493)
7. Balakumar P, Rose M, Singh M, (2007b). PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology 80: 1-10. (Pubitemid 47013361)
8. Balakumar P, Arora MK, Singh M, (2009). Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacol Res 60: 170-173.
9. Balakumar P, Rohilla A, Mahadevan N, (2011). Pleiotropic actions of fenofibrate on the heart. Pharmacol Res 63: 8-12.
10. Blanquart C, Mansouri R, Paumelle R, Fruchart JC, Staels B, Glineur C, (2004). The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. Mol Endocrinol 18: 1906-1918. (Pubitemid 39006498)
11. Chen HH, Chen TW, Lin H, (2010). Pravastatin attenuates carboplatin-induced nephrotoxicity in rodents via peroxisome proliferator-activated receptor alpha-regulated heme oxygenase-1. Mol Pharmacol 78: 36-45.
12. Chen HJ, Chen JZ, Wang XX, Yu M, (2007). PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats. Zhejiang Da Xue Xue Bao Yi Xue Ban 36: 470-476.
13. Chen J, Mehta JL, (2006). Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 291: H1738-H1745. (Pubitemid 44497679)
14. Desjardins F, Sekkali B, Verreth W, Pelat M, De Keyzer D, Mertens A, et al,. (2008). Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. Eur Heart J 29: 128-137.
15. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL, (2004). PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 36: 295-304. (Pubitemid 38202358)
16. Forst T, Wilhelm B, Pfützner A, Fuchs W, Lehmann U, Schaper F, et al,. (2008). Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res 5: 298-303.
17. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH, (2008). Reduction in blood pressure with statins: results from the USCD Statin Study, a randomized trial. Arch Intern Med 168: 721-727. (Pubitemid 351563955)
18. Grip O, Janciauskiene S, Lindgren S, (2002). Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res 51: 58-62. (Pubitemid 34183624)
19. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J, (2005). Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 95: 462-468. (Pubitemid 40247539)
20. Herring N, Lee CW, Sunderland N, Wright K, Paterson DJ, (2011). Pravastatin normalises peripheral cardiac sympathetic hyperactivity in the spontaneously hypertensive rat. J Mol Cell Cardiol 50: 99-106.
21. Huang XS, Zhao SP, Bai L, Hu M, Zhao W, Zhang Q, (2009). Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha. Br J Pharmacol 158: 706-712.
22. Huang XS, Zhao SP, Bai L, Zhang Q, Hu M, Zhao W, (2010). Statin reduced triglyceride level via activating peroxisome proliferator activated receptor α and upregulating apolipoprotein A5 in hypertriglyceridemic rats. Zhonghua Xin Xue Guan Bing Za Zhi 38: 809-813.
23. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, et al,. (2000). Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 67: 863-876. (Pubitemid 30491080)
24. Kapur NK, Musunuru K, (2008). Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag 4: 341-353. (Pubitemid 351711963)
25. Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH, (2010). Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 121: 1868-1877.
26. Kaur J, Reddy K, Balakumar P, (2010). The novel role of fenofibrate in preventing nicotine and sodium arsenite-induced vascular endothelial dysfunction in the rat. Cardiovasc Toxicol 10: 227-238.
27. Kocsis GF, Pipis J, Fekete V, Kovács-Simon A, Odendaal L, Molnár E, et al,. (2008). Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts. Am J Physiol Heart Circ Physiol 294: H2406-H2409.
28. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, et al,. (2005). Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 45: 1649-1653. (Pubitemid 40704501)
29. Leonhardt W, Pfützner A, Müller J, Pietzsch J, Forst T, Karagiannis E, et al,. (2008). Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: a sub-analysis from the PIOSTAT study. Atherosclerosis 201: 155-162.
30. Li X, Liu XP, Liu XH, Du X, Kang JP, Lü Q, et al,. (2010). Effect of statin therapy on mortality in patients with non-ischemic dilated cardiomyopathy. Zhonghua Yi Xue Za Zhi 90: 1974-1977.
31. Liu B, Chen M, Peng HX, Zhang C, Ou ST, (2007). Effects of atorvastatin on expression of peroxisome proliferation activated receptor gamma in unilateral ureteral obstruction in rats. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 19: 739-741. (Pubitemid 351148241)
32. Masumoto A, Hirooka Y, Hironaga K, Eshima K, Setoguchi S, Egashira K, et al,. (2001). Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 88: 1291-1294. (Pubitemid 33132098)
33. Mukhtar RY, Reckless JP, (2005). Statin-induced myositis: a commonly encountered or rare side effect? Curr Opin Lipidol 16: 640-647. (Pubitemid 43012162)
34. Murdock DK, Jansen D, Juza RM, Kersten M, Olson K, Hendricks B, (2006). Benefit of adding pioglitazone to statin therapy in non-diabetic patients with the metabolic syndrome. WMJ 105: 22-25. (Pubitemid 44222724)
35. Nissen SE, Wolski K, (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471. (Pubitemid 46919772)
36. Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y, Goto K, Yamaguchi I, (2002). Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure overloaded rat hearts. Clin Sci 103: 284S-288S. (Pubitemid 35007171)
37. Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I, (2004). Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 43: 1481-1488. (Pubitemid 38496358)
38. Onody A, Zvara A, Hackler L Jr, Vígh L, Ferdinandy P, Puskás LG, (2003). Effect of classic preconditioning on the gene expression pattern of rat hearts: a DNA microarray study. FEBS Lett 536: 35-40. (Pubitemid 36206402)
39. Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, et al,. (2006). Acute antiinflammatory properties of statins involve peroxisome proliferators-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 98: 361-369.
40. Qin YW, Ye P, He JQ, Sheng L, Wang LY, Du J, (2010). Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a 'Western-style diet' by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels. Acta Pharmacol Sin 31: 1350-1358.
41. Ravingerová T, Adameová A, Kelly T, Antonopoulou E, Pancza D, Ondrejcáková M, et al,. (2009). Changes in PPAR gene expression and myocardial tolerance to ischaemia: relevance to pleiotropic effects of statins. Can J Physiol Pharmacol 87: 1028-1036.
42. Rinaldi B, Donniacuo M, Esposito E, Capuano A, Sodano L, Mazzon E, et al,. (2011). PPARα mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure. Br J Pharmacol 163: 609-623.
43. Roglans N, Sanguino E, Peris C, Alegret M, Vázquez M, Adzet T, et al,. (2002). Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther 302: 232-239. (Pubitemid 34680443)
44. Sanguino E, Roglans N, Alegret M, Sánchez RM, Vázquez- Carrera M, Laguna JC, (2005). Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4. Br J Pharmacol 145: 853-861. (Pubitemid 41129006)
45. Schernthaner G, Chilton RJ, (2010). Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us? Diabetes Obes Metab 12: 1023-1035.
46. Shen Y, Wu H, Wang C, Shao H, Huang H, Jing H, et al,. (2010). Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor γ. Eur J Pharmacol 649: 255-262.
47. Sheng L, Ye P, Liu YX, (2005). Atorvastatin upregulates the expression of PPAR alpha/gamma and inhibits the hypertrophy of cardiac myocytes in vitro. Zhonghua Xin Xue Guan Bing Za Zhi 33: 1080-1084.
48. Sugamura K, Sugiyama S, Matsuzawa Y, Nozaki T, Horibata Y, Ogawa H, (2008). Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease. Circ J 72: 1193-1197. (Pubitemid 351957091)
49. Tonstad S, Retterstàl K, Ose L, Ohman KP, Lindberg MB, Svensson M, (2007). The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin. Metabolism 56: 1285-1292. (Pubitemid 47241145)
50. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al,. (1995). Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332: 481-487.
51. Wu J, Song Y, Li H, Chen J, (2009). Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol 65: 1169-1174.
52. Xie L, Lin P, Xie H, Xu C, (2010). Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats. Clin Exp Hypertens 32: 547-554.
53. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, et al,. (2007). Statins activate peroxisome proliferators-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 100: 1442-1451. (Pubitemid 46834756)
54. Ye P, Sheng L, Zhang C, Liu Y, (2006). Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo. J Pharm Pharm Sci 9: 365-375. (Pubitemid 46629864)
55. Zambon A, Cusi K, (2007). The role of fenofibrate in clinical practice. Diab Vasc Dis Res 4: S15-S20. (Pubitemid 350013473)
56. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S, (2002). Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 45: 147-154. (Pubitemid 35425654)